Home » Newsletters » BioWorld Science

BioWorld Science

April 9, 2008

View Archived Issues

Modafinil improves cocaine abstinence in some addicted patients

Recent data on bevacizumab in ocular disorders presented

Reduced retinal thickness seen with VEGF Trap-Eye in neovascular AMD

Ranibizumab under study in patients with pigment epithelial detachments

Visual stability seen with pegaptanib maintenance therapy in neovascular AMD

Callisto files IND with FDA for SP-304 in chronic constipation and irritable bowel syndrome

Transdel receives FDA approval to initiate phase III clinical program for pain drug Ketotransdel

NeuroSearch reports positive results from ongoing phase Ib clinical study of NsG-0202 in AD

Novel analgesic agents imparted in recent Okayama University and Allergan patents

Recent Enanta patents disclose novel therapeutic agents for HCV infection

Recent Biovitrum patents describe novel therapeutic agents for obesity

Novel 5-HT2A inverse agonist shows in vivo efficacy in models of thrombosis

In vitro profile of NK1 antagonist reported at the ACS meeting

Biofrontera presents update on phase III studies of BF-200 ALA in actinic keratosis

Hawaii Biotech receives grant from Pediatric Dengue Vaccine Initiative for dengue vaccine

Urigen closes phase II clinical trial of URG-101 based on positive interim analysis results

Keryx Biopharmaceuticals implements strategic restructuring plan

Biopure receives comment letter regarding U. K. MAA for Hemopure

NovaDel reports positive data from PK study of tizanidine oral spray for spasticity

Knopp Neurosciences initiates phase II KNS-760704 study in ALS

Oncophage approved in Russia for intermediate-risk kidney cancer

Stem cell mobilizer TG-0054 begins phase I study

Generex's Oral-lyn phase III trial begins in North America

FDA approves Orencia for polyarticular juvenile idiopathic arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...